Posted by Michael Wonder on 18 Jul 2025
ICER publishes evidence report on treatments for spinal muscular atrophy
17 July 2025 - There are many remaining uncertainties around the best management of spinal muscular atrophy; ICER estimates that a new therapy for some patients with spinal muscular atrophy, apitegromab, would achieve common thresholds of cost effectiveness if priced between $4,600 - $30,200/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness of nusinersen (Spinraza, Biogen), onasemnogene abeparvovec-xioi (Zolgensma, Novartis), and risdiplam (Evrysdi, Genentech) for spinal muscular atrophy.
